ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P 500
5,495.52
0.45%
US Tech 100
18,331.60
0.84%
Dow Jones
40,736.96
-0.23%
Brent Oil
69.57
0.06%
Bitcoin
56,244.51
-2.46%
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Quince Therapeutics Inc (QNCX) Quote

Quince Therapeutics Inc

Quince Therapeutics Inc (QNCX)

NASDAQ
0.7127
0.0127
(1.81%)
Closed September 11 4:00PM
Delayed by 15 minutes
0.72
0.0073
(1.02%)
After Hours: 7:59PM
Delayed by 15 minutes

Empower your portfolio: Real-time discussions and actionable trading ideas.

Premium

Key stats and details

Current Price
0.7127
Bid
0.6803
Ask
0.77
Volume
97,526
0.68 Day's Range 0.7355
0.5116 52 Week Range 1.4301
Market Cap
30.843M
Previous Close
0.70
Open
0.6801
Last Trade
4
@
0.7484
Last Trade Time
Financial Volume
$ 69,345
VWAP
0.711045
Average Volume (3m)
171,684
Shares Outstanding
43,276,606
Dividend Yield
-
PE Ratio
-2.69
Earnings Per Share (EPS)
-0.73
Revenue
-
Net Profit
-31.39M

About Quince Therapeutics Inc

Quince Therapeutics, Inc. operates as a biopharmaceutical company. The Company focuses on advancing precision therapeutics designed to precisely deliver small molecules, peptides, and large molecules directly to the site of bone diseases to promote more rapid healing with fewer off-target safety con... Quince Therapeutics, Inc. operates as a biopharmaceutical company. The Company focuses on advancing precision therapeutics designed to precisely deliver small molecules, peptides, and large molecules directly to the site of bone diseases to promote more rapid healing with fewer off-target safety concerns. Quince Therapeutics serves customers in the United States. Show more

Sector
Biological Pds,ex Diagnstics
Industry
Biological Pds,ex Diagnstics
Website
quincetx.com
Headquarters
Wilmington, Delaware, USA
Founded
-
Quince Therapeutics Inc is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker QNCX. The last closing price for Quince Therapeutics was $0.70. Over the last year, Quince Therapeutics shares have traded in a share price range of $ 0.5116 to $ 1.4301.

Quince Therapeutics currently has 43,276,606 shares outstanding. The market capitalization of Quince Therapeutics is $30.29 million. Quince Therapeutics has a price to earnings ratio (PE ratio) of -2.69.

Ask ADVFN Intelligence (AI)

QNCX Latest News

More News

Quince Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference

Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases, today announced that...

September 03 2024
Business Wire

Form 4 - Statement of changes in beneficial ownership of securities

August 21 2024
Edgar (US Regulatory)

Quince Therapeutics Announces The Lancet Neurology Publication of Phase 3 ATTeST Clinical Trial Data Evaluating EryDex for the Treatment of Ataxia-Telangiectasia (A-T)

Findings from largest completed study in A-T demonstrated favorable safety profile Study showed positive effect of EryDex treatment in a subset of patients with A-T ages six to nine – the age...

August 15 2024
Business Wire

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

August 13 2024
Edgar (US Regulatory)

Form 8-K - Current report

August 13 2024
Edgar (US Regulatory)

Quince Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial Results

Strong cash position expected to provide sufficient operating runway into 2026; Phase 3 topline results expected in the fourth quarter of 2025 Quince Therapeutics, Inc. (Nasdaq: QNCX), a...

August 13 2024
Business Wire

Quince Therapeutics Announces First Patient Dosed in Phase 3 Clinical Trial of EryDex for the Treatment of Ataxia-Telangiectasia

Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company developing an innovative drug delivery technology designed to leverage a patient’s own biology to deliver rare disease...

June 25 2024
Business Wire

Form 4 - Statement of changes in beneficial ownership of securities

June 07 2024
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

June 07 2024
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

June 07 2024
Edgar (US Regulatory)
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.01271.814285714290.70.73550.6581684190.69875417CS
40.00170.2390998593530.7110.73550.51163872230.58239219CS
120.01271.814285714290.70.870.51161716840.61585167CS
26-0.4273-37.48245614041.141.25430.51161312130.74651682CS
52-0.5473-43.43650793651.261.43010.51161100650.90267659CS
156-88.9273-99.204930834489.6498.50.51166064627.65449864CS
260-20.3273-96.612642585621.04121.980.511643644514.67240836CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
QHQuhuo Ltd
$ 1.36
(315.77%)
346.37M
AILEiLearningEngines Inc
$ 1.60
(120.63%)
81.65M
BKYIBIO key International Inc
$ 1.90
(87.19%)
146.56M
TRVNTrevena Inc
$ 7.67
(50.39%)
686.31k
FBLGFibroBiologics Inc
$ 3.88
(49.23%)
7.19M
EGIOEdgio Inc
$ 0.7632
(-37.44%)
2.8M
PRFXPainReform Ltd
$ 1.05
(-33.96%)
816.4k
SGLYSingularity Future Technology Ltd
$ 1.7801
(-30.19%)
459.53k
ALGSAligos Therapeutics Inc
$ 13.62
(-29.90%)
259.95k
QNRXQuoin Pharmaceuticals Ltd
$ 0.673
(-29.90%)
20.22M
QHQuhuo Ltd
$ 1.36
(315.77%)
346.37M
NVDANVIDIA Corporation
$ 108.10
(1.53%)
268.3M
SQQQProShares UltraPro Short QQQ
$ 9.12
(-2.56%)
160.27M
BKYIBIO key International Inc
$ 1.90
(87.19%)
146.56M
WTOUTime Limited
$ 0.0401
(-15.76%)
141.37M

QNCX Discussion

View Posts
Viewmont Viewmont 4 weeks ago
$QNCX Nice! https://finance.yahoo.com/news/quince-therapeutics-announces-lancet-neurology-110000014.html
👍️0
INFINITI INFINITI 4 weeks ago
Quince Therapeutics Announces The Lancet Neurology Publication of Phase 3 ATTeST Clinical Trial Data Evaluating EryDex for the Treatment of Ataxia-Telangiectasia (A-T)

Source
👍️0
Monksdream Monksdream 4 weeks ago
QNCX new 52 week low
👍️0
Monksdream Monksdream 6 months ago
QNCX
👍️0
Monksdream Monksdream 7 months ago
QNCX under $2
👍️0
AKATITUS AKATITUS 9 months ago
Slow climber
👍️0
Monksdream Monksdream 11 months ago
QNCX under $2
👍️0
AKATITUS AKATITUS 1 year ago
Bought some 1.10s
See what happens
👍️0
knrorrel knrorrel 1 year ago
News https://www.stocktitan.net/news/QNCX/quince-therapeutics-to-acquire-ery-del-sp-a-and-its-phase-3-asset-02yx0yj60e08.html
👍️0
AJ Freely AJ Freely 1 year ago
$QNCX - Up 10% Pre-Market/ Current Price $1.75
To Acquire EryDel SpA and its Phase 3 Asset Targeting Ataxia-Telangiectasia with No Currently Approved Treatments and Estimated $1+ Billion Peak Sales Opportunity
👍️0
AJ Freely AJ Freely 1 year ago
$QNCX- Up 26% Pre-Market/ Current Price $1.24
Echo Lake Capital Increase Offer to Acquire Quince Therapeutics
Increases offer to $1.80 per share + CVR to receive 85% of the future net proceeds of Quince as part of the Lighthouse Pharmaceuticals transaction
👍️0
alchemytrader alchemytrader 1 year ago
Happens. Dirty diluting CEOs
👍️0
Backstabbed Backstabbed 1 year ago
Sorry to hear that
👍️0
alchemytrader alchemytrader 1 year ago
not true. i lost my ass trying to swing PSFE HLBZ FUV. took a terrible loss after finally fiving up. Had i held on i would have lost 90-99% of my money.
👍️0
Backstabbed Backstabbed 1 year ago
all about patience. they all run eventually
👍️0
alchemytrader alchemytrader 1 year ago
congrats
👍️0
Backstabbed Backstabbed 2 years ago
$QNCX - added today!
👍️0
Backstabbed Backstabbed 2 years ago
nice. very low PPS here after it hit a high of $1.75 in PM last week
👍️0
Sirpeter Sirpeter 2 years ago
Hi buddy...added it to watch
👍️0
Backstabbed Backstabbed 2 years ago
$QNCX - News out!!! Quince Therapeutics Provides Pipeline Update and Business Outlook for 2023
👍️0
tw0122 tw0122 2 years ago
$1.33 running again
👍️0
saj saj 2 years ago
Mid 1.3's nice pop on news
👍️0
makinezmoney makinezmoney 2 years ago
$QNCX: Decent bounce move here..... now 0.74


2 days now back to back....................... it was receding since Summer last ear and now finally going


On WATCH


GO $QNCX
👍️0
cash4 cash4 2 years ago
https://www.otcmarkets.com/filing/html?id=15980132&guid=AKk-kW7ZRh7-B3h
👍️0

Your Recent History

NASDAQ
QNCX
Quince Therapeutics
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

United States
Company
Business
Popular
Get The App
App Store
Google Play

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved